Romosozumab for the treatment of postmenopausal women at high risk of fracture

References

• van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and wales. Bone. 2001;29(6):517–522.
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Cummings SR, Stone KL, et al. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res. 2005;20(1):131–140.
   PubMed Web of Science ®Google Scholar
• Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. J Bone Miner Res. 2007;22(6):781–788.
   PubMed Web of Science ®Google Scholar
• Yang J, Cosman F, Stone PW, et al. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective? Osteoporos Int. 2020;31(12):2321–2335.
   PubMed Web of Science ®Google Scholar
• Willers C, Norton N, Harvey NC, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Johansson H, et al. Overview of fracture prediction tools. J Clin Densitom. 2017;20(3):444–450.
   PubMed Web of Science ®Google Scholar
• Wong RMY, Wong PY, Liu C, et al. The imminent risk of a fracture-existing worldwide data: a systematic review and meta-analysis. Osteoporos Int. 2022;33(12):2453–2466.
   PubMed Web of Science ®Google Scholar
• Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007;298(20):2381–2388.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eastell R. Stop (mis)classifying fractures as high- or low-trauma or as fragility fractures. Osteoporos Int. 2020;31(6):1023–1024.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Schousboe JT, Morin SN, et al. Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int. 2020;31(6):1059–1067.
   PubMed Web of Science ®Google Scholar
• Lems WF, Paccou J, Zhang J, et al. Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int. 2021;32(3):399–411.
   PubMed Web of Science ®Google Scholar
• El-Hajj Fuleihan G, Chakhtoura M, Cauley JA, et al. Worldwide fracture prediction. J Clin Densitom. 2017;20(3):397–424.
   PubMed Web of Science ®Google Scholar
• Geusens P, Appelman-Dijkstra NM, Zillikens C, et al. How to implement guidelines and models of care. Best Pract Res Clin Rheumatol. 2022;101759. 10.1016/j.berh.2022.101759
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Johansson H, et al. FRAX update. J Clin Densitom. 2017;20(3):360–367.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Harvey NC, et al. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int. 2022. 10.1007/s00198-022-06567-9.
   Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020;31(2):251–257.
   PubMed Web of Science ®Google Scholar
• Merlijn T, Swart KM, van Schoor NM, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res. 2019;34(11):1993–2000.
   PubMed Web of Science ®Google Scholar
• Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022;34(4):695–714.
   PubMed Web of Science ®Google Scholar
• Johansson L, Johansson H, Axelsson KF, et al. Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporos Int. 2022;33(8):1725–1738.
   PubMed Web of Science ®Google Scholar
• Nguyen TV. Personalized fracture risk assessment: where are we at? Expert Rev Endocrinol Metab. 2021;16(4):191–200.
   PubMed Web of Science ®Google Scholar
• Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080–1092.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract. 2020;26(5):564–570.
   PubMed Web of Science ®Google Scholar
• Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. 2020;105(3):587–594.
   Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Lippuner K, Lamy O, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020;150:w20352.
   PubMed Web of Science ®Google Scholar
• Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.
   PubMed Web of Science ®Google Scholar
• LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–2102.
   Web of Science ®Google Scholar
• Cosman F, Lewiecki EM, Ebeling PR, et al. T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res. 2020;35(7):1333–1342.
   PubMed Web of Science ®Google Scholar
• Cosman F, Dempster DW. Anabolic agents for postmenopausal osteoporosis: how do you choose? Curr Osteoporos Rep. 2021;19(2):189–205.
   PubMed Web of Science ®Google Scholar
• McClung MR, Rothman MS, Lewiecki EM, et al. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med. 2022;134(6):541–551.
   Web of Science ®Google Scholar
• Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–1630.
   PubMed Web of Science ®Google Scholar
• Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. Orthop Nurs. 2020;39(3):145–161.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al., Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017. 377(15): 1417–1427.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al., Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018. 391(10117): 230–240.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. Jama. 2016;316(7):722–733.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11):1932–1941.
   PubMed Web of Science ®Google Scholar
• Chavassieux P, Chapurlat R, Portero-Muzy N, et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res. 2019;34(9):1597–1608.
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–523.
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–1521.
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11–19.
   PubMed Web of Science ®Google Scholar
• Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr Rev. 2013;34(5):658–690.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol. 2016;12(10):593–605.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Hofbauer LC, Forfar JC. Cardiovascular Safety and Sclerostin Inhibition. J Clin Endocrinol Metab. 2021;106(7):1845–1853.
   PubMed Web of Science ®Google Scholar
• Wehmeyer C, Frank S, Beckmann D, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330):330ra35.
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1(6):e27.
   PubMedGoogle Scholar
• Roudier M, Li X, Niu QT, et al. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum. 2013;65(3):721–731.
   PubMedGoogle Scholar
• Kitaura H, Marahleh A, Ohori F, et al. Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int J Mol Sci. 2020;21(14):5169.
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Papapoulos SE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14(10):605–623.
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Papapoulos SE. Sclerostin inhibition in the management of osteoporosis. Calcif Tissue Int. 2016;98(4):370–380.
   PubMed Web of Science ®Google Scholar
• Baron R, Gori F. Targeting WNT signaling in the treatment of osteoporosis. Curr Opin Pharmacol. 2018;40:134–141.
   PubMed Web of Science ®Google Scholar
• Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol. 2015;22:41–50.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Pal S, Chattopadhyay N. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action. Eur J Pharmacol. 2018;826:39–47.
   PubMed Web of Science ®Google Scholar
• Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7(1):11505.
   PubMedGoogle Scholar
• Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312–3322.
   PubMed Web of Science ®Google Scholar
• Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647–2656.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012–1021.
   PubMed Web of Science ®Google Scholar
• Suen PK, Zhu TY, Chow DH, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength of intact bones in adult male rats. Sci Rep. 2015;5(1):15632.
   PubMedGoogle Scholar
• Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948–959.
   PubMed Web of Science ®Google Scholar
• Li X, Niu QT, Warmington KS, et al. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 2014;155(12):4785–4797.
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.
   PubMed Web of Science ®Google Scholar
• Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54(2):168–178.
   PubMed Web of Science ®Google Scholar
• McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935–943.
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216–224.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Graeff C, Campbell GM, Pena J, et al. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364–369.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al., Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016. 375(16): 1532–1543.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Blicharski T, Goemaere S, et al., A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018. 103(9): 3183–3193.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. (London England); 2017. 390(10102): 1585–1594.
   Google Scholar
• Cosman F, Crittenden DB, Ferrari S, et al. Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res. 2018;33(8):1407–1416.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Harvey NC, et al. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021;32(8):1601–1608.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al., One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019. 34(3): 419–428.
   PubMed Web of Science ®Google Scholar
• Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022;33(6):1243–1256.
   PubMed Web of Science ®Google Scholar
• Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32(1):181–187.
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32(9):1956–1962.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Mosekilde L, Langdahl B. Fracture prevention in postmenopausal women. BMJ Clin Evid. 2011;May 3;2011:1109.
   Google Scholar
• Romosozumab. 2019 [cited 2022 Oct 31]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000TOC.cfm
   Google Scholar
• Agency Em. 2019 [cited 2022 Oct 31]. https://www.ema.europa.eu/en/medicines/human/EPAR/evenity
   Google Scholar
• Turk JR, Deaton AM, Yin J, et al. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol. 2020;115:104697.
   PubMed Web of Science ®Google Scholar
• Rodriguez AJ, Abrahamsen B. Cardiovascular safety of antifracture medications in patients with osteoporosis: a narrative review of evidence from randomized studies. JBMR Plus. 2021;5(7):e10522.
   PubMedGoogle Scholar
• Fixen C, Tunoa J. Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep. 2021;19(1):15–22.
   PubMed Web of Science ®Google Scholar
• Fuggle NR, Cooper C, Harvey NC, et al. Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs. 2020;80(15):1537–1552.
   PubMed Web of Science ®Google Scholar
• Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int. 2020;31(6):1019–1021.
   PubMed Web of Science ®Google Scholar
• Chotiyarnwong P, McCloskey EV, Harvey NC, et al. Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International osteoporosis foundation epidemiology/quality of life working group. Arch Osteoporos. 2022;17(1):87.
   PubMed Web of Science ®Google Scholar
• Cornelissen D, Boonen A, Evers S, et al. Improvement of osteoporosis Care Organized by Nurses: ICON study - protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. BMC Musculoskelet Disord. 2021;22(1):913.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bone HG, Massari F, et al., Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019. 30(12): 2437–2448.
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.
   PubMed Web of Science ®Google Scholar
• Vestergaard Kvist A, Faruque J, Vallejo-Yague E, et al. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 2021;10(8):1660.
   PubMed Web of Science ®Google Scholar